types of biomedical R&D projects requiring time and dollars above the amounts specified in applicable Policy Directives.

In signing into law the legislation that established the SBIR program, President Reagan stated, “We in government must work in partnership with small businesses to ensure that technologies and processes are readily transferred to commercial applications.” The program was designed “to strengthen the role of the small, innovative firms in federally funded research and development, and to utilize Federal research and development as a base for technological innovation to meet agency needs and to contribute to the growth and strength of the Nation’s economy.”

In keeping with President Reagan’s directive, NIH believes that it must be able to make SBIR awards to many small biotechnology concerns currently excluded from participation. We look forward to working with you on this important issue.


Elias A. Zerhouni, M.D.


The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement